| Literature DB >> 33531371 |
Pierre-Olivier Frappart1, Alexander Kleger2, Frank Arnold3, Johann Gout3, Heike Wiese4, Stephanie E Weissinger5, Elodie Roger3, Lukas Perkhofer3, Karolin Walter3, Jeanette Scheible3, Caterina Prelli Bozzo6, André Lechel3, Thomas J Ettrich3, Ninel Azoitei3, Li Hao7, Axel Fürstberger8, Ewa K Kaminska9, Konstantin M J Sparrer6, Volker Rasche7, Sebastian Wiese4, Hans A Kestler8, Peter Möller5, Thomas Seufferlein3.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) still presents with a dismal prognosis despite intense research. Better understanding of cellular homeostasis could identify druggable targets to improve therapy. Here we propose RAD50-interacting protein 1 (RINT1) as an essential mediator of cellular homeostasis in PDAC. In a cohort of resected PDAC, low RINT1 protein expression correlated significantly with better survival. Accordingly, RINT1 depletion caused severe growth defects in vitro associated with accumulation of DNA double-strand breaks (DSB), G2 cell cycle arrest, disruption of Golgi-endoplasmic reticulum homeostasis, and cell death. Time-resolved transcriptomics corroborated by quantitative proteome and interactome analyses pointed toward defective SUMOylation after RINT1 loss, impairing nucleocytoplasmic transport and DSB response. Subcutaneous xenografts confirmed tumor response by RINT1 depletion, also resulting in a survival benefit when transferred to an orthotopic model. Primary human PDAC organoids licensed RINT1 relevance for cell viability. Taken together, our data indicate that RINT1 loss affects PDAC cell fate by disturbing SUMOylation pathways. Therefore, a RINT1 interference strategy may represent a new putative therapeutic approach. SIGNIFICANCE: These findings provide new insights into the aggressive behavior of PDAC, showing that RINT1 directly correlates with survival in patients with PDAC by disturbing the SUMOylation process, a crucial modification in carcinogenesis. ©2021 American Association for Cancer Research.Entities:
Year: 2021 PMID: 33531371 DOI: 10.1158/0008-5472.CAN-20-2633
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701